Showing results (101-110 of 756) with videos related to

Sort By:
Pageof 76
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Optimum timing of treatment for hepatitis C infection relative to liver transplantationAudrey Coilly, Bruno Roche, Jean-Charles Duclos-Vallée, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
The mesentery: structure, function, and role in diseaseJ Calvin Coffey, D Peter O'Leary
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Genetics of inflammatory bowel disease: beyond NOD2Maša Umićević Mirkov, Bram Verstockt, Isabelle Cleynen
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trialKohei Shitara, Atsuo Takashima, Kazumasa Fujitani, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort studyFiona M Walter, Katie Mills, Silvia C Mendonça, et al.
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and ChinaGilaad G Kaplan, Siew C Ng
The Lancet. Gastroenterology & Hepatology|April 14, 2017
Antifibrotics in chronic liver disease: tractable targets and translational challengesPrakash Ramachandran, Neil C Henderson
The Lancet. Gastroenterology & Hepatology|July 22, 2019
Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trialOlga C Aroniadis, Lawrence J Brandt, Caterina Oneto, et al.
The Lancet. Gastroenterology & Hepatology|July 27, 2019
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trialStefan Traussnigg, Jörn M Schattenberg, Münevver Demir, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2022
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyJames L Alexander, Nicholas A Kennedy, Hajir Ibraheim, et al.
Pageof 76